Navigation Links
GenVec Reports Fourth Quarter And 2012 Year-End Financial Results
Date:3/22/2013

s decreased 18% to $14.3 million in 2012 from $17.4 million in 2011.  In 2012 we experienced lower research and development costs than in the prior year due primarily to decreased manufacturing costs in the hearing and FMD programs, the closeout of the PACT trial, reduced personnel costs as a result of our reduction in force, reduced material costs for our funded programs, and reduced equipment purchases under our hearing and FMD programs.  These decreases were partially offset by increased outside costs for our other research programs as compared to 2011.

General and administrative expenses increased 17% to $9.1 million in 2012 from $7.8 million in 2011.  General and administrative expenses were higher in 2012 primarily due to personnel costs, which included approximately $1.3 million in non-recurring employment costs.

Fourth Quarter 2012 ResultsFor the fourth quarter ended December 31, 2012, GenVec reported a net loss of $3.2 million, or $0.24 per share, compared with a net loss of $2.5 million, or $0.19 per share, for the comparable prior year period.  The Company reported revenues of $1.5 million in the fourth quarter of 2012 compared to $3.4 million for the same period in 2011.  This decrease was primarily due to reduced revenue related to both our hearing loss and balance disorders program, $1.3 million, and FMD program, $0.2 million.  Reduced revenue in each case is due to a reduced work scope in the 2012 period as compared to the same period in 2011.  Research and development expenses decreased 21% in 2012 from $3.9 million in the fourth quarter of 2011 to $3.1 million in the fourth quarter of 2012 due mainly to reduced personnel and manufacturing costs.  General and administrative expenses in the fourth quarter of 2012 decreased 20% to $1.6 million from $2.0 million in the comparable period in 2011 primarily due to decreased personnel and recruiting costs, partially offset by higher professional costs.
'/>"/>

SOURCE GenVec, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. GenVec To Release First Quarter 2012 Financial Results And Conduct A Conference Call On May 10, 2012
2. GenVec Appoints Cynthia Collins as President and CEO
3. GenVec Reports Inducement Award
4. GenVec Announces Conditional Approval of FMD Vaccine for Cattle
5. GenVec to Release Second Quarter 2012 Financial Results and Conduct a Conference Call on August 9, 2012
6. GenVec Reports Second Quarter 2012 Financial Results
7. GenVec Reports Third Quarter 2012 Financial Results
8. GenVec to Present at 25th Annual ROTH Conference
9. GenVec To Release Fourth Quarter And Year-end 2012 Financial Results And Conduct A Conference Call On March 22, 2013
10. Qmed, the Leading Global MedTech Industry Resource, Partners with Clarimed, to Provide the Medical Manufacturing and Healthcare Industry with FDA Reports on Adverse Events
11. Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... , Oct. 30, 2014  Zimmer Holdings, Inc. ... announced the future executive leadership team and organizational structure ... Biomet transaction.  Zimmer also announced that the combined organization ... will be named Zimmer Biomet, with the new brand ... the closing of the merger.  The future leadership team ...
(Date:10/30/2014)... NEW YORK , Oct. 30, 2014  The ... United States is growing steadily, thanks to ... years, as a result of the economic downturn, retail ... was a year of opportunities, as the number of ... market researcher,s report, Retail Clinics Market Overview and ...
(Date:10/30/2014)... 30, 2014 China Biologic Products, Inc. (NASDAQ: ... integrated plasma-based biopharmaceutical company in China ... third quarter 2014 financial results on Wednesday, November 5, ... Company,s management will hold a conference call at 7:30 ... is 8:30 p.m., Beijing Time on November 6, 2014, ...
Breaking Medicine Technology:Zimmer Announces Executive Leadership Team and New Name of Combined Company Following Closing 2Zimmer Announces Executive Leadership Team and New Name of Combined Company Following Closing 3Zimmer Announces Executive Leadership Team and New Name of Combined Company Following Closing 4Zimmer Announces Executive Leadership Team and New Name of Combined Company Following Closing 5Zimmer Announces Executive Leadership Team and New Name of Combined Company Following Closing 6Zimmer Announces Executive Leadership Team and New Name of Combined Company Following Closing 7Zimmer Announces Executive Leadership Team and New Name of Combined Company Following Closing 8Zimmer Announces Executive Leadership Team and New Name of Combined Company Following Closing 9Report: Drugstore Chains Drive Retail Clinic Growth 2Report: Drugstore Chains Drive Retail Clinic Growth 3China Biologic to Report Third Quarter 2014 Financial Results 2
... REGN ) today announced that the Company ... agreement (Agreement) with Genentech, Inc., a member of the ... U.S. ophthalmic sales of EYLEA™ (aflibercept) Injection. ... relating to VEGF receptor proteins, known as the Davis-Smyth ...
... testing, the gold standard in hypothyroid diagnosis, may be ... article titled Hormone Replacement Therapy in the ... for the Future. Estrogen, Progesterone, Testosterone, and Thyroid Hormone ... independently written and published, is a broad study of ...
Cached Medicine Technology:Regeneron Announces Settlement of Patent Litigation with Genentech for U.S. Ophthalmic Sales of EYLEA™ (aflibercept) Injection 2Regeneron Announces Settlement of Patent Litigation with Genentech for U.S. Ophthalmic Sales of EYLEA™ (aflibercept) Injection 3Studies Show That TSH Is Unreliable in the Diagnosis of Hypothyroidism According to Article Contributed by Kent Holtorf, M.D. in Clinical Geriatrics 2
(Date:10/30/2014)... cancer care respects the fact that a patient,s ... requires treatment. Over a third of cancer patients ... of their conditions. And, increasingly, care providers are ... patients navigate mental health challenges. A University of ... journal Psycho-Oncology asks an important question: ...
(Date:10/29/2014)... The development of minimally and even non-invasive technologies is ... for instance, to carry out a range of operative ... scalpel, leaving only tiny scars as a result. Similar ... active agents to patients – instead of using injections ... be possible to supply them via a plaster which ...
(Date:10/29/2014)... certain prostate cancer medications are linked with an increased ... congestive heart failure or prior heart attacks. Published in ... and patients weigh the benefits and risks of the ... levels of male hormones in the body to prevent ... treatment for prostate cancer. Despite its anticancer effects, ADT ...
(Date:10/28/2014)... and outer body and organ surfaces in the human ... in the inner ear," said Moritz Gegg. Cilia – ... are precisely positioned on many of these epithelial cells. ... coordinated so precisely that for example mucus can be ... from sensory inner ear hair cells," added Heiko Lickert. ...
(Date:10/28/2014)... NY (October 27, 2014)—Although oral hormonal therapy is ... women with hormone receptor–positive tumors, about one-half of ... A study by Columbia University Medical Center (CUMC) ... aromatase inhibitors (the most common type of hormone ... brand-name counterparts, increased treatment adherence by 50 percent. ...
Breaking Medicine News(10 mins):Health News:Decades of research: Effectiveness of phone counseling for cancer patients still unknown 2Health News:Gentle caffeine boost for premature babies 2Health News:Prostate cancer medications linked with increased risk of heart-related deaths in men with cardiovascular problems 2Health News:New insights into the development of ciliopathies 2Health News:Generic medications boost adherence to breast cancer therapy 2Health News:Generic medications boost adherence to breast cancer therapy 3
... , MONDAY, Jan. 17 (HealthDay News) -- Patients at high ... detect the deadly skin cancer at an early stage, new ... some people from having a doctor examine their skin for ... Archives of Dermatology . People at high risk for ...
... HealthDay Reporter , MONDAY, Jan. 17 (HealthDay News) -- ... flares of multiple sclerosis (MS), but does not help ... guidelines say. Plasma exchange, or plasmapheresis, is also ... chronic inflammatory demyelinating polyneuropathy and it may be considered ...
... poor can prevent young children from reaching their full genetic potential ... University of Texas at Austin looked at 750 sets of twins ... and 2 years. During the tests the children were asked to ... placing three cubes in a cup, and matching pictures. At ...
... HealthDay Reporter , MONDAY, Jan. 17 (HealthDay News) -- ... called calcium channel blockers face an increased risk of ... shock if they take certain antibiotics, Canadian researchers warn. ... to patients taking calcium channel blockers, can increase the ...
... -- Among middle-school students, friendships can make the difference ... Students whose friends are socially active in positive ways ... badly get lower grades, according to the results of ... also staying away from deviant peers was associated with ...
... surgery remains significantly different when compared to the patient,s opposite ... a study that updated prior findings, researchers used X-rays providing ... relation to the shoulder blade, to compared motion in the ... tendon tears and no symptoms in their other shoulders. An ...
Cached Medicine News:Health News:Thorough Exams a Must for Those at High Risk of Skin Cancer 2Health News:Thorough Exams a Must for Those at High Risk of Skin Cancer 3Health News:Some Severe MS Flares Helped by Blood Filtering Treatment 2Health News:Some Severe MS Flares Helped by Blood Filtering Treatment 3Health News:Some Antibiotics, Blood Pressure Meds a Bad Mix: Study 2Health News:Some Antibiotics, Blood Pressure Meds a Bad Mix: Study 3Health News:Friends a Big Influence on Grades in Middle School: Study 2Health News:Henry Ford Hospital study: Shoulder function not fully restored after surgery 2
Cocoon Disposable Patient Warming Blankets are specially designed to prevent hypothermia and maintain normothermia in your patients. The soft warm coloured material is strong and resists tearing and ...
The design of the large pediatric underbody blanket conveniently warms the large child or small adult patient while allowing full access for surgeons and staff....
Similar to Model 530, but just 37 inches long and with only one drape....
2-ply material consisting of polyethylene film inner layer and non-woven outer layers. Polyethylene cover....
Medicine Products: